Syncom Formulations (India) Ltd.
Snapshot View

View in App

Prices View details >>

5.98 +0.99 ▲19.8%

29 March 2023, 04:01:00 PM
Volume: 961,873

Overview View Details >>

Sector Healthcare Compare with Sector peers
Industry Pharmaceuticals & Drugs Compare with Industry peers
Website http://www.sfil.in
Market Cap 562.12 Cr.
Enterprise Value(EV) 649.28 Cr. 2022-09
Financial Indicators
Earnings per share (EPS) 0.17 Trailing Twelve Months Ending 2022-12
Price-Earning Ratio (PE) 34.34 Trailing Twelve Months Ending 2022-12
Industry PE 32.17 Trailing Twelve Months Ending 2022-12
Book Value / Share 2.62 Trailing Twelve Months Ending 2022-12
Price to Book Value 2.29 Calculated using Price: 5.98
Dividend Yield 0.00 Period Ending 2022-03
No. of Shares Subscribed 94.00 Cr. 940,000,000 Shares
FaceValue 1
Company Profile
Syncom Formulations (India) Ltd was originally incorporated as Syncom Formulations (India) Private Limited in the state of Maharashtra on June 21, 1988 under the Companies Act, 1956. Further the status of company was changed to public limited company and thereby name of company changed to Syncom Formulations (India) Limited and a fresh certificate of change of name obtained on July 9, 1992.

Delivery View Details >>

Delivered Qty
Traded Qty

Performance View Details >>

1 Day
+19.84%
1 Week
-1.16%
1 Month
-3.39%
3 Month
-34.14%
6 Month
-25.62%
1 Year
-43.96%
2 Year
+94.16%
5 Year
+516.49%
10 Year
+175.58%

Ratios View Details >>

9 years 2014-03 2015-03 2016-03 2017-03 2018-03 2019-03 2020-03 2021-03 2022-03
Return on Equity (%) 10.19 9.99 9.91 9.56 7.33 8.71 10.24 18.04 10.02
Return on Capital Employed (%) 15.29 15.55 14.72 13.58 9.43 9.37 12.39 20.72 10.61
Return on Assets (%) 6.95 6.82 6.41 5.93 4.90 6.34 7.92 12.27 6.60

Balance Sheet View Details >>

Particulars 10 years 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2022-03 Rs. Cr. 2022-09* Rs. Cr.
Shh. Funds 95 100 109 114 122 133 146 188 222 242
Non Curr. Liab. 7 6 6 8 9 8 7 7 8 9
Curr. Liab. 42 37 66 56 43 36 31 97 78 126
Minority Int.
Equity & Liab. 144 143 181 179 174 176 184 292 308 377
Non Curr. Assets 66 59 89 92 93 95 95 102 168 193
Curr. Assets 78 83 92 87 81 81 89 190 140 184
Misc. Exp. not W/O
Total Assets 144 143 181 179 174 176 184 292 308 377

Profit Loss View Details >>

Particulars 10 years 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2022-03 Rs. Cr. 2022-12 Rs. Cr. TTM
Net Sales 151 173 184 185 159 187 206 245 220 222
Other Income 1 2 3 3 4 5 5 7 12 14
Total Income 152 175 187 188 163 192 211 252 232 235
Total Expenditure -135 -155 -167 -168 -147 -175 -189 -207 -200 -206
PBIDT 17 20 19 19 16 17 22 45 32 29
Interest 0 0 0 0 0 0 -1 0 -2 -3
Depreciation -3 -3 -3 -3 -4 -4 -4 -4 -4 -4
Taxation -5 -6 -6 -5 -3 -2 -3 -12 -6 -6
Exceptional Items -1 0 0 0 0 0 0 0
PAT 9 10 10 11 9 11 14 29 20 16
Adjusted EPS 0 0 0 0 0 0 0 0 0 0

Cash Flow View Details >>

Particulars 10 years 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2022-03 Rs. Cr.
Cash Fr. Operatn. 6 7 0 24 17 -2 4 6 -2 16
Cash Fr. Inv. 0 -4 1 -23 -8 -2 2 2 -75 -27
Cash Fr. Finan. -6 -1 1 -2 -2 -2 0 -7 72 8
Net Change -1 2 2 -1 6 -6 7 1 -5 -2
Cash & Cash Eqvt 4 5 7 6 7 1 7 8 3 0

Shareholding Pattern View Details >>

9 Qtrs 2020-12 (%) 2021-03 (%) 2021-06 (%) 2021-09 (%) 2021-12 (%) 2022-03 (%) 2022-06 (%) 2022-09 (%) 2022-12 (%)
Promoter 40.48 41.18 41.18 44.01 44.01 46.12 50.57 50.57 50.57
Public 59.52 58.82 58.82 55.99 55.99 53.88 49.43 49.43 49.43
Depository Receipts 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Promoter Holding Pledge (%) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00

Announcements View Details >>

Wed, 15 Feb 2023
Announcement under Regulation 30 (LODR)-Newspaper Publication
Pursuant to Regulation 30 read with Schedule III Part A(A)and in compliance of Regulation 47(1)(b) of SEBI (LODR) Regulations 2015 regarding extract of Standalone and Consolidated Un-Audited Quarter and Nine Month ended Financial Results for the Quarter and Nine Month ended 31st December 2022 was also approved by the Audit Committee and Board of Directors at their meeting held on Monday 13th February 2023.We herewith enclose the newspaper advertisement published on 15th February 2023 in Free Press Journal English edition and Marathi (vernacular) Newspaper.
Mon, 13 Feb 2023
Submission Of The Statement Of Deviation Pursuant To Regulation 32(1) For The Quarter Ended 31St December 2022 As Per SEBI (LODR) Regulations 2015.
Pursuant to Regulation 32(1) of SEBI (LODR) Regulations 2015 and SEBI Circular No. CIR/CFD/CMD1/162/2019 dated December 24 2019 issued by the SEBI titled "Format on Statement of Deviation or Variation for proceeds of public issue rights issue preferential issue Qualified Institutions Placement (QIP) etc."We are pleased to submit NIL Statement of deviation and further there is no modification in the project and the fund utilized for the Quarter ended 31st December 2022.
Mon, 13 Feb 2023
Submission Of The Un-Audited Standalone And Consolidated Financial Results Along With Limited Review Report Thereon For The Quarter And Nine Months Ended 31St December 2022 As Per Regulation 33(3)(D) Of SEBI (LODR) Regulations 2015
This is in continuation of our letter no. SYNCOM/SE/2022-23 dated 2nd February 2023 regarding intimation of Board meeting for consideration and approval of Standalone and Consolidated Un-Audited Financial Results for the Quarter and Nine Months ended 31st December 2022.Pursuant to Regulation 33 of SEBI (LODR) Regulations 2015 we are pleased to the following:1. Standalone and Consolidated Unaudited Financial Results of the Company for the Quarter and Nine Months ended on 31st December 2022;2. Standalone and Consolidated Limited Review Report by the Statutory Auditors of the company for the Quarter and Nine Months ended on 31st December 2022.which was considered and approved by the Board at their 7/2022-23 Meeting held on Monday the 13th February 2023.The meeting of the Board of Directors commenced at 4:00 P.M. and concluded at 8:00 P.M.

Technical Scans View Details >>

Wed, 29 Mar 2023
Closing Above Previous High Closing Above Previous High
Close Below Last Month Low Close Below Last Month Low
High Decrease in 3 Months High Decrease in 3 Months
High Decrease in 6 Months High Decrease in 6 Months
High Decrease in 1 Year High Decrease in 1 Year

Related Stocks View Details >>

  • SALES
Stock Name Market Cap(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. 237,702.12 990.70 +0.7%
Dr. Reddy's Laboratories Ltd. 76,011.65 4,564.50 +0.8%
Divi's Laboratories Ltd. 74,827.63 2,818.70 +0.5%
Cipla Ltd. 71,662.87 887.85 -0.2%
Apollo Hospitals Enterprise Ltd. 62,756.97 4,371.75 +1.0%
Torrent Pharmaceuticals Ltd. 52,113.83 1,554.65 +0.7%
Zydus Lifesciences Ltd. 49,628.37 490.30 +1.2%
Stock Name Statement TTM Ending Price Earning Ratio(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-12 56.44 990.70 +0.7%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-12 20.86 4,564.50 +0.8%
Divi's Laboratories Ltd. Consolidated 2022-12 31.22 2,818.70 +0.5%
Cipla Ltd. Consolidated 2022-12 27.16 887.85 -0.2%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-12 82.20 4,371.75 +1.0%
Torrent Pharmaceuticals Ltd. Consolidated 2022-12 63.32 1,554.65 +0.7%
Zydus Lifesciences Ltd. Consolidated 2022-12 24.08 490.30 +1.2%
Stock Name Statement TTM Ending Price To Book Value(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-12 4.30 990.70 +0.7%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-12 3.45 4,564.50 +0.8%
Divi's Laboratories Ltd. Consolidated 2022-12 6.01 2,818.70 +0.5%
Cipla Ltd. Consolidated 2022-12 3.16 887.85 -0.2%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-12 10.19 4,371.75 +1.0%
Torrent Pharmaceuticals Ltd. Consolidated 2022-12 8.25 1,554.65 +0.7%
Zydus Lifesciences Ltd. Consolidated 2022-12 2.88 490.30 +1.2%
Stock Name Statement Year Ending Debt Equity Ratio LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-03 0.03 990.70 +0.7%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 0.18 4,564.50 +0.8%
Divi's Laboratories Ltd. Consolidated 2022-03 0.00 2,818.70 +0.5%
Cipla Ltd. Consolidated 2022-03 0.04 887.85 -0.2%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-03 0.47 4,371.75 +1.0%
Torrent Pharmaceuticals Ltd. Consolidated 2022-03 0.68 1,554.65 +0.7%
Zydus Lifesciences Ltd. Consolidated 2022-03 0.25 490.30 +1.2%
Stock Name Statement Year Ending Return On Equity(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-03 7.21 990.70 +0.7%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 11.93 4,564.50 +0.8%
Divi's Laboratories Ltd. Consolidated 2022-03 28.16 2,818.70 +0.5%
Cipla Ltd. Consolidated 2022-03 13.10 887.85 -0.2%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-03 21.60 4,371.75 +1.0%
Torrent Pharmaceuticals Ltd. Consolidated 2022-03 13.18 1,554.65 +0.7%
Zydus Lifesciences Ltd. Consolidated 2022-03 15.51 490.30 +1.2%
Stock Name Statement Year Ending Return On Capital Employed(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-03 7.21 990.70 +0.7%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 11.93 4,564.50 +0.8%
Divi's Laboratories Ltd. Consolidated 2022-03 28.16 2,818.70 +0.5%
Cipla Ltd. Consolidated 2022-03 13.10 887.85 -0.2%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-03 21.60 4,371.75 +1.0%
Torrent Pharmaceuticals Ltd. Consolidated 2022-03 13.18 1,554.65 +0.7%
Zydus Lifesciences Ltd. Consolidated 2022-03 15.51 490.30 +1.2%
Stock Name Statement Year Ending Net Sales(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-03 38,654.49 990.70 +0.7%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 21,545.20 4,564.50 +0.8%
Divi's Laboratories Ltd. Consolidated 2022-03 8,959.83 2,818.70 +0.5%
Cipla Ltd. Consolidated 2022-03 21,763.34 887.85 -0.2%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-03 14,662.60 4,371.75 +1.0%
Torrent Pharmaceuticals Ltd. Consolidated 2022-03 8,508.04 1,554.65 +0.7%
Zydus Lifesciences Ltd. Consolidated 2022-03 15,265.20 490.30 +1.2%
Stock Name Statement Year Ending Profit After Tax(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-03 3,405.82 990.70 +0.7%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 2,182.50 4,564.50 +0.8%
Divi's Laboratories Ltd. Consolidated 2022-03 2,960.45 2,818.70 +0.5%
Cipla Ltd. Consolidated 2022-03 2,559.47 887.85 -0.2%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-03 1,101.10 4,371.75 +1.0%
Torrent Pharmaceuticals Ltd. Consolidated 2022-03 777.18 1,554.65 +0.7%
Zydus Lifesciences Ltd. Consolidated 2022-03 2,326.40 490.30 +1.2%

FAQ's On Syncom Formulations (India) Ltd.

What is Syncom Formulations share price?
Can I buy Syncom Formulations shares now?
What is the Market Cap of Syncom Formulations?
What are the key metrics to analyse Syncom Formulations?
What is the 52 Week High and Low of Syncom Formulations?
What is the trend of Syncom Formulations share price?